Who are MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mva-bn-filo-1-10-8-infectious-unit-inf-u.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] — Competitive Intelligence Brief

MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] (MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant viral vector vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant viral vector vaccine Filovirus glycoproteins (Ebola virus GP, Marburg virus GP) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] (MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]) — Janssen Vaccines & Prevention B.V.. MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
*MVA-BN-Filo 110^8 Infectious Unit [Inf. U.]** TARGET	MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]	Janssen Vaccines & Prevention B.V.	phase 3	Recombinant viral vector vaccine	Filovirus glycoproteins (Ebola virus GP, Marburg virus GP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant viral vector vaccine class)

Janssen Vaccines & Prevention B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] — Competitive Intelligence Brief. https://druglandscape.com/ci/mva-bn-filo-1-10-8-infectious-unit-inf-u. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab